h lundbeck a/s (HLUKF:Grey Market)

Last $20.09 USD

Change Today +0.39 / 1.98%

Volume 310.0

HLUKF On Other Exchanges

Symbol

Exchange

Copenhagen

As of 8:10 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (HLUKF) Snapshot

Open $20.09		Previous Close $19.70
Day High $20.09		Day Low $20.09
52 Week High 05/23/12 - $21.05		52 Week Low 12/21/12 - $14.20
Market Cap --		Average Volume 10 Days 54.0
EPS TTM --		Shares Outstanding 0.0
EX-Date 03/22/13		P/E TM --
Dividend $2.02		Dividend Yield 1.73%

Current Stock Chart for H LUNDBECK A/S (HLUKF)

HLUKF:US Historical Stock Quote
HLUKF:US Advanced Stock Chart

Related News

No related news articles were found.

h lundbeck a/s (HLUKF) Related Businessweek News

Europe Pushes to Keep Lethal Injection Drugs From U.S. Prisons

02/07/2013 5:45 PM ET

View More BusinessWeek News

h lundbeck a/s (HLUKF) Details

H. Lundbeck A/S, a specialty pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of brain disorders in Europe, the United States, and internationally. The company’s principal products include Cipralex and Lexapro to treat depression, Ebixa for Alzheimer’s disease, Azilect to treat Parkinson’s disease, Xenazine for chorea associated with Huntington's disease, Sabril to treat epilepsy, Sycrest for bipolar disorder, and Onfi to treat Lennox-Gastaut syndrome. Its compounds in registration application include aripiprazole IM depot for the treatment of schizophrenia; Selincro for alcohol dependence; and Brintellix for the treatment of depression and anxiety. The company’s products in Phase III trials comprise IV carbamazepine for epilepsy; Brexpiprazole for psychiatric disorders; Desmoteplase for stroke; and Zicronapine for psychosis. Its products in Phase II trials include Tedatioxetine for depression and Lu AE58054 for Alzheimer's disease. The company was founded in 1915 and is based in Valby, Denmark.

Detailed HLUKF:US Company Description...

www.lundbeck.com

5,379 Employees
Last Reported Date: 05/1/13

Founded in 1915

Latest 10-K

Latest 10-Q

More HLUKF SEC Filings...

h lundbeck a/s (HLUKF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (HLUKF) Key Developments

H.Lundbeck A/S Launches Selincro in the United Kingdom

May 7 13

Biotie announced that its partner H.Lundbeck A/S has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of EUR 2 million related to the UK launch. Biotie will potentially contribute to Lundbeck towards any required post approval commitment studies. Lundbeck will continue the rollout of Selincro in additional European markets through 2013 and into 2014.

H. Lundbeck A/S Unveils Treatment for Reduction of Alcohol Consumption

May 2 13

H. Lundbeck A/S has announced that the company has shipped Selincro in its first markets and has made the product available for alcohol dependent patients with high-risk drinking levels in Norway, Finland, Poland and the Baltic countries. In clinical trials, Selincro reduced alcohol consumption by approximately 60% after six months treatment.

H. Lundbeck A/S, Q1 2013 Earnings Call, May 01, 2013

May 1 13

H. Lundbeck A/S, Q1 2013 Earnings Call, May 01, 2013